---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-005779"
form_type: "8-K"
ticker: "PMI"
cik: "0002030617"
company_name: "Picard Medical, Inc."
filed_at: "2026-05-29T11:05:27+00:00"
generated_at: "2026-05-29T11:11:17.258106+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Picard Medical Q1 revenue up 85%, gross margin 24%; NYSE listing notice received

## Summary
- Q1 2026 revenue $1.2M (+85% YoY); gross profit margin 24% vs. -58% in Q1 2025.
- 2025 total revenue $4.9M (+12.5%); IPO raised $17.4M net; year-end cash $11.5M.
- Repaid $7.4M senior debt in Q1; post-quarter public offering raised $5.0M gross.
- Next-gen Emperor TAH second-gen animal testing completed May 2026; FDA submission target 2028.
- NYSE American notified of stockholders' equity deficiency; compliance plan due June 7, 2026.

## SEC filing metadata
- accession: 0001829126-26-005779
- form_type: 8-K
- ticker: PMI
- cik: 0002030617
- company_name: Picard Medical, Inc.
- filed_at: 2026-05-29T11:05:27+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030617/000182912626005779/0001829126-26-005779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030617/000182912626005779/picardmedical_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-005779
- JSON: https://secwatch.observer/filing/0001829126-26-005779.json
- Plain text: https://secwatch.observer/filing/0001829126-26-005779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.